10-Q: Nurix Therapeutics Reports Increased Revenue and Advancements in Clinical Pipeline, Despite Widening Losses

Nurix Therapeutics, a clinical-stage biopharmaceutical company, reported a significant increase in total revenue driven by new license agreements, alongside a substantial rise in research and development expenses leading to increased net losses, while advancing its lead drug candidates and securing key regulatory designations.

Summary

• Total revenue for the three months ended May 31, 2025, increased to $44.056 million from $12.092 million in the prior year period, primarily due to $30.0 million in license revenue from Sanofi.
• Total revenue for the six months ended May 31, 2025, increased to $62.509 million from $28.677 million in the prior year period.
• Net loss for the three months ended May 31, 2025, was $43.464 million, compared to $44.546 million for the same period in 2024.
• Net loss for the six months ended May 31, 2025, was $99.815 million, compared to $86.064 million for the same period in 2024.
• Research and development expenses increased by $29.174 million to $78.096 million for the three months ended May 31, 2025, and by $48.832 million to $147.759 million for the six months ended May 31, 2025, driven by accelerated clinical trial enrollment and increased contract research costs.
• General and administrative expenses increased by $2.572 million to $14.282 million for the three months ended May 31, 2025, and by $2.427 million to $25.936 million for the six months ended May 31, 2025, due to increased headcount and consulting costs.
• Cash, cash equivalents, and marketable securities totaled $485.8 million as of May 31, 2025, down from $609.583 million as of November 30, 2024.
• The company has an accumulated deficit of $838.6 million as of May 31, 2025.
• Bexobrutideg (NX-5948) received Fast Track designation from the FDA for relapsed or refractory CLL/SLL and Waldenström macroglobulinemia (WM), and Orphan Drug Designation for WM from the FDA and for lymphoplasmacytic lymphoma (including WM) from the EMA.
• The partial clinical hold on the U.S. Phase 1a/1b study evaluating zelebrudomide (NX-2127) was lifted by the FDA in March 2024, and enrollment reinitiated in August 2024 with a new drug product.
• The company is eligible to receive up to approximately $6.1 billion in total future fees and milestone payments, plus royalties, from its collaborations with Gilead, Sanofi, and Pfizer.
• As of May 31, 2025, $204.6 million of common stock remained available for sale under the Second Amended Equity Distribution Agreement (ATM program).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company experienced widening net losses and increased cash burn, these are typical for a clinical-stage biopharmaceutical company accelerating its pipeline. Significant positives include substantial revenue growth from new license agreements, the lifting of a clinical hold on a key candidate, and multiple Fast Track and Orphan Drug designations for bexobrutideg, indicating strong regulatory support and potential for accelerated development. The large potential future milestone payments from collaborations also provide a strong long-term outlook, despite the acknowledged need for future capital raises.

Positives

• Total revenue significantly increased for both the three and six months ended May 31, 2025, primarily driven by $30.0 million in license revenue from Sanofi.
• Bexobrutideg (NX-5948) received multiple positive regulatory designations, including two FDA Fast Track designations (for CLL/SLL and WM) and two Orphan Drug Designations (for WM from FDA and lymphoplasmacytic lymphoma from EMA), which can accelerate development and provide market exclusivity.
• The FDA lifted the partial clinical hold on zelebrudomide (NX-2127) in March 2024, allowing reinitiation of enrollment in August 2024, indicating progress in addressing prior concerns.
• NX-1607 was awarded an Innovation Passport from the UK MHRA, aiming to accelerate time to market and facilitate patient access.
• The company has substantial potential future payments from collaborations, with up to $6.1 billion in contingent payments and royalties from Gilead, Sanofi, and Pfizer.
• Management believes existing cash, cash equivalents, and marketable securities of $485.8 million are sufficient to fund operations for at least the next 12 months.

Negatives

• Net loss increased to $99.815 million for the six months ended May 31, 2025, from $86.064 million in the prior year period, indicating widening losses.
• Research and development expenses increased substantially by $48.832 million for the six months ended May 31, 2025, reflecting high costs associated with clinical development and research activities.
• The company has incurred significant losses since inception, with an accumulated deficit of $838.6 million as of May 31, 2025, and does not expect to achieve profitability in the near future.
• Cash, cash equivalents, and marketable securities decreased from $609.583 million as of November 30, 2024, to $485.8 million as of May 31, 2025.
• The company has never generated revenue from product sales and expects it will be many years, if ever, before a drug candidate is ready for commercialization.
• The company will need substantial additional funding beyond the next 12 months to complete development and commercialization of its drug candidates.

Risks

• Incurred significant losses since inception and expects to incur losses for at least the next several years, potentially never achieving or maintaining profitability.
• Will need substantial additional funding; inability to raise capital when needed may delay, limit, reduce, or terminate research, product development, or commercialization efforts.
• Early stage of development for lead drug candidates (bexobrutideg, zelebrudomide, NX-1607), with high risk of failure.
• Limited operating history makes it difficult to evaluate business success and future viability.
• Potential for serious adverse events, undesirable side effects, or unexpected characteristics of drug candidates, which could lead to abandonment or limitation of clinical development.
• Results of preclinical studies and early-stage clinical trials may not be predictive of future results, and initial success may not be indicative of later-stage trial outcomes.
• Difficulty or inability to obtain and maintain Orphan Drug Designation or other regulatory designations, or maintain associated benefits like market exclusivity.
• Risk that drug candidates are not considered new active substances or fall within existing marketing authorizations, potentially failing to obtain regulatory data protection or extensions.
• Substantial competition in an environment of rapid technological change, potentially leading to others developing or commercializing products more successfully.
• Dependence on collaborations with third parties (Gilead, Sanofi, Pfizer) for research, development, and commercialization, with risks of non-success or termination.
• Reliance on third-party contract manufacturing organizations (CMOs) for drug substance and finished drug product, increasing risk of insufficient quantities, unacceptable cost/quality, or delays.
• Inability to obtain and maintain patent protection for technology and drug candidates, or insufficient breadth of protection, allowing competitors to commercialize similar products.
• Risk of not identifying relevant third-party patents or incorrectly interpreting their relevance/scope, leading to potential intellectual property infringement allegations and legal proceedings.
• Unfavorable global economic conditions (inflation, interest rate fluctuations, market volatility, geopolitical conflicts) could adversely affect business, financial condition, and stock price.
• Failure to attract and retain management and other key personnel could hinder successful development and commercialization.
• Even if commercialized, products may face unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, or fail to secure positive health technology assessments.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Disruptions at the FDA or other regulatory agencies (e.g., government shutdowns) could slow review/approval times.
• Changes in U.S. federal income tax reform and other tax laws could adversely affect the company.
• Ability to utilize net operating loss carryforwards may be subject to limitations due to ownership changes.
• Future acquisitions, joint ventures, spin-outs, or strategic alliances could disrupt business and harm financial condition.
• Subject to anti-corruption laws, export control laws, customs laws, sanctions laws, and other laws governing operations, with potential for civil/criminal penalties for non-compliance.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or significant costs.
• Operations concentrated in San Francisco Bay Area, vulnerable to earthquakes or other natural disasters.
• Quarterly results of operations may fluctuate significantly or fall below expectations, causing stock price volatility.
• Future sale and issuance of equity or convertible debt securities will dilute share capital.
• No significant additional funds from pre-funded warrant exercises, but exercise increases shares eligible for resale and causes dilution.
• Anti-takeover provisions in charter documents and Delaware law could make acquisitions more difficult.
• Exclusive forum provisions in charter documents could limit stockholders' ability to obtain a favorable judicial forum.
• Increased costs and management time required for operating as a public company and compliance initiatives.
• Risk of failing to maintain effective internal control over financial reporting.
• No longer qualifies as a 'smaller reporting company,' leading to increased disclosure and reporting requirements.
• No anticipated cash dividends, making capital appreciation the sole source of gain for stockholders.
• Potential for securities litigation, which is expensive and could divert management attention.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities to be sufficient to fund operating activities for at least the next 12 months. However, substantial additional funding will be required to support continuing operations and pursue the long-term business plan, including advancing drug candidates through clinical development, scaling manufacturing, and seeking marketing approvals. Expenses are expected to increase substantially as clinical trials progress and the pipeline expands. The company aims to establish degrader-based treatments at the forefront of patient care and continues to leverage its DEL-AI platform for new drug candidates.

Management Comments

• "We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the degradation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions and other challenging diseases."
• "Leveraging the Company’s expertise in E3 ligases together with its proprietary DNA-encoded libraries, the Company has built DEL-AI, a fully AI-integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can degrade proteins within the cell."
• "Our wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells."
• "We expect to initiate a Phase 2 clinical trial of bexobrutideg in 2025."
• "In August 2024, we reinitiated enrollment [for zelebrudomide] with a new chirally controlled drug product, which is being evaluated in a dose escalation study within the Phase 1a/b trial."
• "In aggregate, we have received $482.0 million in non-dilutive financing from our collaborators to date and as of May 31, 2025, we are eligible to receive up to $6.1 billion in potential future fees and milestone payments, as well as royalties on future product sales."
• "Management believes that its cash, cash equivalents and marketable securities are sufficient to continue operating activities for at least 12 months following the issuance date of these condensed financial statements."
• "To finance our operations beyond that point, we will need to raise substantial additional capital to complete the development and commercialization of our drug candidates."

Industry Context

Nurix Therapeutics operates in the highly competitive and rapidly evolving biopharmaceutical industry, specifically focusing on targeted protein degradation, a novel treatment modality. While this approach holds significant promise for various diseases, it is still unproven with no targeted protein degraders yet approved in the U.S. or Europe. The company faces competition from both traditional small molecule therapies and other advanced modalities like gene editing and cell therapy. Its collaborations with major pharmaceutical companies like Gilead, Sanofi, and Pfizer are crucial for validating its DEL-AI platform and advancing its pipeline, providing non-dilutive funding and shared development responsibilities. The industry is also subject to increasing regulatory scrutiny, particularly regarding drug pricing and data privacy, and is impacted by global macroeconomic conditions.

Comparison to Industry Standards

• The company's focus on targeted protein degradation places it in an emerging but highly competitive field, with many other biotechnology companies and large pharmaceutical players investing in similar approaches. No targeted protein degraders have yet received regulatory approval in the U.S. or Europe, making Nurix's progress with bexobrutideg, zelebrudomide, and NX-1607 significant within this nascent therapeutic area.
• The receipt of Fast Track and Orphan Drug designations for bexobrutideg aligns with industry efforts to accelerate development for serious conditions with unmet needs, similar to designations granted to other innovative oncology and rare disease candidates by the FDA and EMA.
• The substantial increase in R&D expenses is typical for clinical-stage biopharmaceutical companies accelerating patient enrollment and preparing for pivotal trials, reflecting the high costs inherent in drug development, comparable to peers at similar stages of clinical advancement.
• The company's reliance on collaborations with major pharmaceutical companies (Gilead, Sanofi, Pfizer) for funding and development expertise is a common strategy in the biotech industry, especially for companies with novel platforms like DEL-AI, allowing for risk sharing and leveraging larger partners' resources and market access capabilities.
• The accumulated deficit and ongoing net losses are standard for clinical-stage biotech companies that have not yet commercialized products, as significant upfront investment is required before potential product sales can generate revenue.

Legal Proceedings

• The company is not presently a party to any material legal proceedings.
• In May 2025, the company received new information from the California Franchise Tax Board (FTB) and remeasured an unrecognized tax benefit for California revenue sourcing, resulting in discrete tax expense. The company intends to enter into Settlement procedures with the FTB in the next twelve months.

Related Party Transactions

• The company's Chief Financial Officer is a trustee for the multiple employer welfare association that facilitates the acquisition and administration of the company's healthcare plans. Expenses related to healthcare plan premiums were $1.5 million for the three months ended May 31, 2025, and $2.8 million for the six months ended May 31, 2025.

Stakeholder Impact

• **Shareholders**: Potential for dilution from future capital raises, but also potential for significant long-term value creation if drug candidates achieve commercial success and large collaboration milestones are met. Current losses and cash burn are a concern.
• **Employees**: Increased headcount and compensation costs indicate growth and investment in personnel. The 2024 Equity Inducement Plan and Employee Stock Purchase Plan are mechanisms for employee incentives and retention.
• **Customers (Future Patients)**: Progress in clinical trials and regulatory designations for bexobrutideg, zelebrudomide, and NX-1607 offers hope for new treatment options for cancer and inflammatory conditions.
• **Suppliers/Vendors**: Continued reliance on third-party contract manufacturing organizations (CMOs) and contract research organizations (CROs) for development and manufacturing, indicating ongoing business for these partners.
• **Collaborators (Gilead, Sanofi, Pfizer)**: Continued engagement and potential for significant milestone payments and royalties, reinforcing the value of the partnerships and the DEL-AI platform.

Next Steps

• Initiate a Phase 2 clinical trial of bexobrutideg (NX-5948) in 2025.
• Continue Phase 1a/1b dose-escalation and cohort expansion studies for bexobrutideg, zelebrudomide (NX-2127), and NX-1607.
• Advance additional drug candidates into preclinical and clinical development using the DEL-AI platform.
• Seek marketing approvals for any drug candidates that successfully complete clinical trials.
• Establish sales, marketing, and distribution infrastructure for commercialization, if approvals are obtained.
• Expand, maintain, and protect the intellectual property portfolio.
• Hire additional clinical, regulatory, manufacturing, quality assurance, and scientific personnel.
• Continue to improve operational, financial, and management controls as a public company.
• Enter into Settlement procedures with the California Franchise Tax Board (FTB) in the next twelve months regarding tax assessments.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Targeted Protein Degradation, DEL-AI Platform, Oncology, Autoimmune Diseases, Bexobrutideg, NX-5948, Zelebrudomide, NX-2127, NX-1607, Clinical Stage, Drug Development, SEC Filing, 10-Q, Biotechnology, Clinical Trials, BTK Degrader, CBL-B Inhibitor, Collaboration Agreements, Gilead Sciences, Sanofi, Pfizer, Fast Track Designation, Orphan Drug Designation, Financial Results, Research and Development, Capital Raise, Biotech Investment